Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bupivacaine Liposome Injection for Postoperative Pain After Thoracoscopic Surgery
NCT06529432Phase 2Recruiting
- Sponsor
- Hengrui
- Start
- Mar 2026
- Primary completion
- Nov 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of bupivacaine liposome in postoperative pain, sponsored by Hengrui. Primary endpoint: Area under the time curve of pain intensity during exercise (or cough) for 72 hours after administration. Started Mar 2026; status: recruiting.
02
Drugs
bupivacaine liposome
03
Conditions
postoperative pain
Beyond the preview
Go deeper on NCT06529432.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06529432.